Semaglutide trial investigates effects on energy intake, appetite, glucose, and gastric emptying in obese subjects

Despite the efficacy of current weight loss interventions, long-term maintenance of weight loss remains a significant challenge for individuals with obesity. Existing studies on semaglutide have demonstrated short-term reductions in energy intake, appetite, and food reward, contributing to initial weight loss. However, the sustained mechanisms by which semaglutide influences these factors, particularly its long-term effects on eating behaviors and metabolic parameters crucial for weight maintenance, are not fully elucidated. This trial seeks to bridge this knowledge gap by comprehensively assessing semaglutide's impact on key physiological drivers of energy balance.

This Phase 1 randomized, placebo-controlled trial was designed to investigate the effects of semaglutide on various metabolic and appetite-related endpoints in obese subjects. Participants were randomized to receive either semaglutide or placebo. The primary objectives included assessing changes in energy intake, subjective appetite sensations, postprandial glucose and triglyceride metabolism, and gastric emptying rates. Specific doses, routes, and durations of semaglutide administration were not detailed in the trial registration, nor was the exact sample size (n) or specific assay methodologies (ELISA, qPCR).